key: cord-0854096-9o2lai1g
authors: Dhindsa, Sandeep; Zhang, Nan; McPhaul, Michael J.; Wu, Zengru; Ghoshal, Amit K.; Erlich, Emma C.; Mani, Kartik; Randolph, Gwendalyn J.; Edwards, John R.; Mudd, Philip A.; Diwan, Abhinav
title: Association of Circulating Sex Hormones With Inflammation and Disease Severity in Patients With COVID-19
date: 2021-05-25
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.11398
sha: f135be44081041199eeee65aaeddc076fe7b6179
doc_id: 854096
cord_uid: 9o2lai1g

IMPORTANCE: Male sex is a risk factor for developing severe COVID-19 illness. It is not known whether sex hormones contribute to this predisposition. OBJECTIVE: To investigate the association of concentrations of serum testosterone, estradiol, and insulinlike growth factor 1 (IGF-1, concentrations of which are regulated by sex hormone signaling) with COVID-19 severity. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted using serum samples collected from consecutive patients who presented from March through May 2020 to the Barnes Jewish Hospital in St Louis, Missouri, with COVID-19 (diagnosed using nasopharyngeal swabs). EXPOSURES: Testosterone, estradiol, and IGF-1 concentrations were measured at the time of presentation (ie, day 0) and at days 3, 7, 14, and 28 after admission (if the patient remained hospitalized). MAIN OUTCOMES AND MEASURES: Baseline hormone concentrations were compared among patients who had severe COVID-19 vs those with milder COVID-19 illness. RNA sequencing was performed on circulating mononuclear cells to understand the mechanistic association of altered circulating hormone concentrations with cellular signaling pathways. RESULTS: Among 152 patients (90 [59.2%] men; 62 [40.8%] women; mean [SD] age, 63 [16] years), 143 patients (94.1%) were hospitalized. Among 66 men with severe COVID-19, median [interquartile range] testosterone concentrations were lower at day 0 (53 [18 to 114] ng/dL vs 151 [95 to 217] ng/dL; P = .01) and day 3 (19 [6 to 68] ng/dL vs 111 [49 to 274] ng/dL; P = .006) compared with 24 men with milder disease. Testosterone concentrations were inversely associated with concentrations of interleukin 6 (β = −0.43; 95% CI, −0.52 to −0.17; P < .001), C-reactive protein (β = −0.38; 95% CI, −0.78 to −0.16; P = .004), interleukin 1 receptor antagonist (β = −0.29; 95% CI, −0.64 to −0.06; P = .02), hepatocyte growth factor (β = −0.46; 95% CI, −0.69 to −0.25; P < .001), and interferon γ–inducible protein 10 (β = −0.32; 95% CI, −0.62 to −0.10; P = .007). Estradiol and IGF-1 concentrations were not associated with COVID-19 severity in men. Testosterone, estradiol, and IGF-1 concentrations were similar in women with and without severe COVID-19. Gene set enrichment analysis revealed upregulated hormone signaling pathways in CD14(+)CD16(−) (ie, classical) monocytes and CD14(−)CD16(+) (ie, nonclassical) monocytes in male patients with COVID-19 who needed intensive care unit treatment vs those who did not. CONCLUSIONS AND RELEVANCE: In this single-center cohort study of patients with COVID-19, lower testosterone concentrations during hospitalization were associated with increased disease severity and inflammation in men. Hormone signaling pathways in monocytes did not parallel serum hormone concentrations, and further investigation is required to understand their pathophysiologic association with COVID-19.

We utilized serum samples that were prospectively collected from patients who presented to the Barnes Jewish Hospital in Saint Louis, MO with symptoms suggestive of COVID-19 illness and were confirmed to have SARS-CoV-2 infection with nasopharyngeal swabs. Testosterone, estradiol, and IGF-1 were measured by liquid chromatography-mass spectrometry at the time of presentation to the hospital (baseline or day 0) and at days 3, 7, 14 and 28 after admission (if the patient remained hospitalized).

Owing to limited sample volumes available, assays for total testosterone, estradiol, and IGF-1 were performed following dilution into charcoal stripped serum as follows: total testosterone for this assay were 250-1100 ng/dL in adult males 2 and 2-45 ng/dl in adult females. The performing laboratory is certified by Clinical Laboratory Improvement Amendments and is a participant in the Hormone Standardization program of the Centers for Disease Control and Prevention.

LC-MS/MS methodology was also used to measure total estradiol. The method was similar to that previously described 3 , with some improvements After adding 300 µL of ethanol spiked with internal standards (17β-Estradiol-2,3,4-13 C3) to 200 µL of patient serum, the mixture was incubated in an ice slurry for 30 minutes before centrifugation. 50 µL of the supernatant was injected onto a multiplex High Performance Liquid Chromatography (HPLC) system equipped with an online turbo flow extraction system (Cohesive Technologies Inc.; Franklin, MA, part of Thermo Fisher Scientific) for further clean up and separation from the matrix. The online extraction and HPLC columns were Phenomenex Strata C18-E (70 um, 50x1.0 mm; P/N 00B-S001-A0) and Phenomenex Biphenyl (2.6 um, 100Å, 50x3.0 mm; P/N AF0-5727) respectively.

Estradiol and its internal standard were detected by a triple quadrupole mass spectrometer (Sciex reference range is ≤29 pg/mL for men, 39-440 pg/mL for premenopausal women and ≤10 pg/mL for postmenopausal women.

IGF-1 was measured by highly accurate LC-MS method similar to the method described previously. 4 100 μL aliquots of patient sera were mixed with 10 μL of internal standard (15N- The inter assay precision (CV) of the IGF-1 assay is 8.79% at 40 ng/mL, 6.43% at 177 ng/mL, and 5.97% at 358 ng/mL. The LOQ for IGF-1 assay is 8 ng/mL. The reference ranges of IGF-1 vary by age and gender and have been described previously 5 . integrity was determined using Agilent Bioanalyzer or 4200 Tapestation. Library preparation was performed with 10ng of total RNA with a Bioanalyzer RIN score greater than 8.0. ds-cDNA was prepared using the SMARTer Ultra Low RNA kit for Illumina Sequencing (Takara-Clontech) per manufacturer's protocol. cDNA was fragmented using a Covaris E220 sonicator using peak incident power 18, duty factor 20%, cycles per burst 50 for 120 seconds. cDNA was blunt ended, had an A base added to the 3' ends, and then had Illumina sequencing adapters Ensembl and SARS-CoV-2 gene models. Sequencing performance was assessed for the total number of aligned reads, total number of uniquely aligned reads, and features detected.

Differential expression analysis to determine genes that differed with severe disease for each cell 10 read counts across all samples were removed prior to analysis. Gene Set Enrichment Analysis (v4.0.3) 9 was performed using the GSEAPreranked tool against the Hallmark gene set (v7.2).

Genes were ranked using the sign of the fold change times the -log10(p-value) and otherwise default parameters.

We assessed the relation of testosterone, estradiol, and IGF-1 concentrations during the hospitalization with COVID severity, ICU and ventilator use, mortality and inflammatory cytokines using univariate and multivariate regression and mixed model analyses. These models addressed missing data values by maximum likelihood, under the data missing at random assumption. Sensitivity analyses were performed to evaluate this assumption. Based on these analyses, missing at random assumption was deemed reasonable. The comparisons were adjusted for age, BMI, race, smoking and co-morbidities at baseline (Charlson Comorbidity Index, CCI).

CCI is a validated method to determine significant medical comorbidity. It considers 17 common medical conditions that predict one-year mortality. These include myocardial infarction, heart failure, peripheral arterial disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, liver disease, diabetes (including diabetes with end organ damage), hemiplegia, renal disease, leukemia, lymphoma, solid tumors, and AIDS. Medical diagnoses are weighted for severity and summed to provide a weighted index of medical comorbidity with total scores ranging from 0-33. 

Insulinlike Growth Factor 1 Concentrations During Hospital Stay in Male Patients Values are median

Sample Multiplexing: Increased Throughput for Quantification of Total Testosterone in Serum by Liquid Chromatography-Tandem Mass Spectrometry

Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe

Methods for Detecting Estradiol by mass Spectrometry

Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: determination of insulin-like growth factor-1. Analytical chemistry

Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry

STAR: ultrafast universal RNA-seq aligner

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles